Thomas Lynch

Thomas Lynch at Yale was co-first author of the landmark 2004 paper identifying activating EGFR mutations in lung cancer as predictors of response to gefitinib, a discovery that opened the era of precision oncology in lung cancer. This work, simultaneously published with Paez et al., transformed NSCLC from a single disease to a collection of molecular subtypes each with distinct therapeutic implications. His subsequent research has contributed to understanding EGFR inhibitor resistance mechanisms and optimal treatment sequences. His foundational contribution to EGFR-mutant lung cancer remains one of the most impactful discoveries in thoracic oncology.